找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Bladder Cancer; A Practical Guide Ashish M. Kamat,Peter C. Black Book 2021 Springer Nature Switzerland AG 2021 TURBT.Adjvuant Intravescial

[复制链接]
楼主: 小缺点
发表于 2025-3-28 16:09:36 | 显示全部楼层
发表于 2025-3-28 21:42:03 | 显示全部楼层
发表于 2025-3-29 01:15:16 | 显示全部楼层
Transurethral Resection of Bladder Tumors (TURBT)surgery has been shown to have a significant impact on oncologic outcome. Imaging techniques such as blue light cystoscopy have been proven to further improve detection rates and oncologic outcomes. The impact of en bloc resection on recurrence and progression rates is currently under investigation.
发表于 2025-3-29 04:58:08 | 显示全部楼层
发表于 2025-3-29 09:00:32 | 显示全部楼层
发表于 2025-3-29 15:09:19 | 显示全部楼层
Adjuvant Intravesical Chemotherapy. 68:7–30, 2018) About 75% of these newly diagnosed cases are nonmuscle-invasive bladder cancer (NMIBC). With such a large percentage of all bladder cancer patients having nonmuscle-invasive disease at diagnosis, it is fitting that the American Urological Association has a guideline specifically add
发表于 2025-3-29 16:08:16 | 显示全部楼层
Device-Assisted Therapies for Nonmuscle-Invasive Bladder Cancer: A Practical Approach(NMIBC) or in the case of limited supply of conventional drugs. Device-assisted therapy can be done with hyperthermia or an electrical current. Based on (limited) published literature and personal experience, three methods of device-assisted therapy, which are currently mostly used in clinical trial
发表于 2025-3-29 22:42:58 | 显示全部楼层
Intravesical Salvage Therapy After BCG/Regular Chemoy is the mainstay of frontline therapy; however, recurrence will still occur for 40–80% of patients over a 10-year period. Radical cystectomy with urinary diversion remains the standard of care for many of these patients; however, recent evidence suggests that this is underutilized as many patients
发表于 2025-3-30 01:49:48 | 显示全部楼层
Oncological Monitoring of NonMuscle Invasive Bladder Cancer (NMIBC) cancer (NMIBC) comprises the majority of these cases and is known for its varying oncological outcomes and need for frequent follow-up and treatment. However, there is significant heterogeneity between surveillance protocols and an undefined role for the implementation of new endoscopic technology
发表于 2025-3-30 06:54:36 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-21 06:16
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表